脂蛋白a与心血管疾病的临床研究进展  

Progress of Clinical Research on Lipoprotein a and Cardiovascular Diseases

作　　者：郑采尹 刘增长[1] 

机构地区：[1]重庆医科大学附属第二医院心血管内科,重庆

出　　处：《临床医学进展》2024年第2期2320-2327,共8页Advances in Clinical Medicine

摘　　要：脂蛋白a作为一种低密度脂蛋白胆固醇样颗粒,它很大程度上是由遗传决定的。Lp(a)升高已被证实与动脉粥样硬化性心血管疾病(ASCVD)、心房颤动、主动脉瓣钙化等疾病风险增加相关。本篇文章主要回顾脂蛋白a的病理生理学,关于脂蛋白a的认识指南,相关临床研究与当前正在开发的新疗法。Lipoprotein a is a lipoprotein particle similar to low-density lipoprotein cholesterol, which is pri-marily determined by genetic factors. Elevated levels of Lp(a) have been associated with an in-creased risk of atherosclerotic cardiovascular disease (ASCVD), atrial fibrillation, and calcification of the aortic valve. This article provides an overview of the pathophysiology of lipoprotein a, guidelines for understanding it, relevant clinical studies, and ongoing developments in new therapies.

关 键 词：脂蛋白A 冠状动脉疾病 心房颤动 小干扰RNA 

分 类 号：R54[医药卫生—心血管疾病]